Navigation Links
Positive Final Data from HyCAMP Phase II Trial in Metastatic,Colorectal

BRISBANE, Australia, May 29, 2007 /PRNewswire/ -- Phase II results exceed expectations - Alchemia prepares for FDA talks on HyCAMP(TM)

Australian drug development company Alchemia Limited will commence discussions with the US Food and Drug Administration (FDA) following the successful conclusion of the Phase II clinical trial of its metastatic colorectal cancer treatment, HyCAMP(TM).

The final data from the randomized Phase II clinical trial in 80 patients with metastatic colorectal cancer treated with HyCAMP(TM) versus Camptosar(R) shows:


    - HyCAMP(TM) exerted superior anti-cancer activity with a significantly

      greater number of patients with observed tumour responses


    - A statistically significant increase in 'time to treatment failure'

      demonstrating that HyCAMP(TM) patients were able to stay on treatment

      longer due to reduced toxicity and increased efficacy


    - A significantly longer period (+116%) of 'progression-free survival' for

      patients receiving HyCAMP(TM)*


    - Patients on HyCAMP(TM) were able to receive therapy for a median of

      three times longer than those receiving Camptosar(R)*


    - A clinically significant trend towards longer overall survival for

      patients receiving HyCAMP(TM)


    - HyCAMP(TM) patients received less doses of anti-diarrheal medication

      than Camptosar(R) patients


    - This data was announced to the ASX on April 26 2007

Alchemia Chief Executive Officer, Dr Peter Smith said, "The fact that we are seeing statistically significant improvements in efficacy end-points from such a small study is a reflection of the substantial increase in anti-tumour activity seen with HyCAMP(TM). Generally, much larger studies would be required to show such effects. This data is an exceptional validation of our HyACT(TM) drug delivery technology platform and its application to the treatment of cancer
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Positive Final Data from HyCAMP Phase Trial Metastatic Colorectal
(Date:8/3/2015)... , Aug. 3, 2015 Par Pharmaceutical ... conference call on Friday, August 7, 2015 at 9:00 ... the second quarter ended June 30, 2015.  Par is ... to the public in its filings with the Securities ... available on its website by following the instructions at ...
(Date:8/3/2015)... , Aug. 3, 2015 OmniSeq, LLC ... Institute to the OmniSeq SM Genomic Network.  ... Cancer Institute (RPCI) and announced it was making ... a physician-driven, collaborative approach to genomic diagnostics that ... Cancer Institute is a rapidly expanding, multidisciplinary cancer ...
(Date:8/3/2015)...  Sage Analytics ( www.sageanalytics.com ), the developers of ... systems, announced its sponsorship of the California Cannabis Industry ... number of tickets are available for groups or individuals ... while enjoying an open bar, buffet dinner and hors ... Bay at sunset. With the legislative session ...
Breaking Medicine Technology:OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 2OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 3Sage Analytics Sponsors California Cannabis Industry Association Bay Area Cruise FUNdraiser 2
... YORK, April 9, 2008 Intra-Cellular Therapies, ... ongoing development,programs for ITI-007, the Company,s first-in-class ... and ITI-722,a low-dose formulation of ITI-007, which ... respectively. These new data demonstrate,ITI-007 has preclinical ...
... ... - Preliminary Phase I/II results to be presented in June at 2008 ... ... ), a clinical-stage biopharmaceutical company,focused on oncology, announced today that it has advanced CR011-vcMMAE, ...
Cached Medicine Technology:Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722 2Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722 3CuraGen Advances CR011-vcMMAE into Phase II 2CuraGen Advances CR011-vcMMAE into Phase II 3CuraGen Advances CR011-vcMMAE into Phase II 4
(Date:8/3/2015)... ... August 03, 2015 , ... The Workgroup for Electronic Data Interchange ... to create efficiencies in healthcare information exchange, announced the release of its findings from ... Human Services (HHS) Secretary, WEDI shared survey results and recommendations , ...
(Date:8/3/2015)... Angeles, California (PRWEB) , ... August 03, 2015 ... ... on the Atlanta Journal Constitution, the new Lifetime reality series, “Atlanta Plastic” ... who performs and who receives plastic surgery, with its predominantly African-American cast of ...
(Date:8/3/2015)... ... August 03, 2015 , ... According to an opinion piece published July 28 by ... to one pound of weight loss may not be accurate. While this system may work ... pound of fat varies – based both on the individual and at what point that ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... They know ... Providence St. Vincent Medical Center offers some of the best care in the ... neurosurgeon and neurointerventionalist, achieved the fastest average blood clot removal time in the country. ...
(Date:8/3/2015)... Pennsylvania (PRWEB) , ... August 03, 2015 , ... Bayer ... Yaz and Yasmin related claims in which a claimant alleged to have suffered an ... related to the birth control pills, Yaz, Yasmin and Ocella, has been ongoing for ...
Breaking Medicine News(10 mins):Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 3Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 4Health News:Article on Lifetime’s New “Atlanta Plastic” Reality Series Underlines the Diversity of Today’s Plastic Surgery Patients, Says Plastic Surgeon Dr. J 2Health News:Article on Lifetime’s New “Atlanta Plastic” Reality Series Underlines the Diversity of Today’s Plastic Surgery Patients, Says Plastic Surgeon Dr. J 3Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 2Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 3Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2
... reflect results of new study , , FRIDAY, Jan. 18 (HealthDay ... American women carries a risk of serious blood clots that ... control pill, the U.S. Food and Drug Administration warned ... study that discovered the increased danger, the agency said it ...
... in Vegan Diet War, WASHINGTON, Jan. 18 ... the misleading Physicians Committee,for Responsible Medicine (PCRM) for ... which sued eight restaurant chains this week,over the ... been exposed,in Newsweek and The New York Times ...
... the United States Food and,Drug Administration (FDA) has ... cholesterol lowering medication also indicated for,improving glycemic control ... in,combination with metformin, sulfonylureas, or insulin, when these ... anti-diabetic agents., The ADA estimates that 20.8 ...
... Jan. 18 175 students from,the Academy of Columbus, ... the sixth annual Give Kids A Smile! Day state ... state kick-off will be held in the Atrium at ... from,The Ohio State University College of Dentistry, legislators and ...
... aggressive disease in 2 men taking the product , , ... product described as a dietary supplement appears to have ... two men, researchers report. , "There were things on ... components in the product that were not on the ...
... Part of Available Resources-, JACKSONVILLE, Fla., Jan. ... group of returning wounded veterans are the most ... has expanded,their ever-evolving battery of programs and services ... initiative., The Warriors to Work (WtoW) program ...
Cached Medicine News:Health News:FDA Warns Clot Risk Higher in Birth Control Patch Than Pill 2Health News:FDA Warns Clot Risk Higher in Birth Control Patch Than Pill 3Health News:Phony 'Physicians Committee' Suing Restaurants is Animal-Rights Trojan Horse, says CCF 2Health News:MultiVu Video Feed: WELCHOL (R) (COLESEVELAM HCL) RECEIVES FDA APPROVAL FOR GLUCOSE CONTROL IN ADULTS WITH TYPE 2 DIABETES MELITUS 2Health News:Statehouse Atrium to be Site for Children's Dental Access Event - Ohio Legislators to Mingle With Children and Dentists for This Free Care Event! 2Health News:Mislabled Supplement Spurred Prostate Cancer: Report 2Health News:Mislabled Supplement Spurred Prostate Cancer: Report 3Health News:Wounded Warrior Project (WWP) Expands Service Offerings for Injured Soldiers with the New 'Warriors to Work' Program 2
... HIV-1 Genotyping: The genome of ... in an infected patient, especially in response ... mutations have been shown to render the ... drugs, diminishing the effectiveness of the treatment.,The ...
EIA for Donor Screening. Synthetic peptide Enzyme Immunoassay (EIA) for the detection of antibodies to Human Immunodeficiency Virus Types 1 and/or 2,(HIV-1 and HIV-2) in human serum, plasma or ca...
... The Reveal Rapid HIV-1 Antibody Test (Reveal ... This test detects antibodies in human serum ... by the body in response to HIV ... MedMiras proprietary flow-through membrane technology, and is ...
... The OraQuick ADVANCE ... is a single-use, qualitative ... to Human Immunodeficiency Virus ... Type 2 (HIV-2) in ...
Medicine Products: